Sponsored Links
| MAP Pharmaceuticals Submits New Drug Application To FDA For LEVADEX® Orally Inhaled Migraine Drug |
 |
 |
 |
| Medical News - Headache Migraine | |||
|
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults... Read more: Headache / Migraine News From Medical News Today
|